StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Zirabev [legacy through FY23] by Quarter

Zirabev (bevacizumab biosimilar) [legacy through FY23] — International reported YoY (%) (%)

QuarterlyAnnual

Pfizer Zirabev [legacy through FY23]: -34.0% in Q4 2023, down 5.0 pts from a year earlier. That is the lowest of the 10 quarters on record here. No newer figure appears in the documents we track.

Latest, Q4 2023
-34.0%
Period ended Dec 31, 2023
Change on a year earlier
-5.0 pts
-29.0% in Q4 2022
History
10 quarters
Since Q3 2021
Sources
10
Documents cited below

Where the Q4 2023 figure comes from

“|| Zirabev | 88 | 130 | (32%) | (32%) | 66 | 97 | (31%) | 22 | 33 | (34%) | (32%)”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗

Reported in Form 8-K Revenue Tables.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedZirabev (bevacizumab biosimilar) [legacy through FY23] — International reported YoY (%) (%)Year on yearSource
Q4 2023Dec 31, 2023-34.0%-5.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Q3 2023Oct 1, 2023-1.0%+15.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-10012023xex99.htm, filed 2023-10-31) ↗
Q2 2023Jul 2, 2023-20.0%+9.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-07022023xex99.htm, filed 2023-08-01) ↗
Q1 2023Apr 2, 2023-23.0%0.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-04022023xex99.htm, filed 2023-05-02) ↗
Q4 2022Dec 31, 2022-29.0%-27.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗
Q3 2022Oct 2, 2022-16.0%-66.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-10022022xex99.htm, filed 2022-11-01) ↗
Q2 2022Jul 3, 2022-29.0%–Form 8-K (Earnings / Guidance Release) (pfe-07032022xex99.htm, filed 2022-07-28) ↗
Q1 2022Apr 3, 2022-23.0%–Form 8-K (Earnings / Guidance Release) (pfe-04032022xex99.htm, filed 2022-05-03) ↗
Q4 2021Dec 31, 2021-2.0%–Form 8-K (Earnings / Guidance Release) (pfe-12312021xex99.htm, filed 2022-02-08) ↗
Q3 2021Oct 3, 202150.0%–Form 8-K (Earnings / Guidance Release) (pfe-10032021xex99.htm, filed 2021-11-02) ↗

Cite this data

StockData. (2026). Pfizer Zirabev [legacy through FY23] (%), quarterly Q3 2021–Q4 2023 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/zirabev-leg-yoy-intl

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.